La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Biora Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Biora Therapeutics..

Biora Therapeutics (NASDAQ:BIOR) Azioni, Catena delle Opzioni

Biora Therapeutics

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

Biora Therapeutics Inc

BioRegenx Inc

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

Biorem Inc

Biora Therapeutics (BIOR) just unveiled an update. Biora Therapeutics, Inc. has initiated a strategic financial maneuver involving a debt exchange ...

Biora Therapeutics Restructures Debt and Issues New Securities

Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Biora Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bior-stock-quote/"><strong>BIOR</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Biora Therapeutics reported earnings per share of -4 cents. This was above the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $318,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/bior-stock-earnings-biora-therapeutics-for-q2-of-2024/">BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report), with a pr...

Biora Therapeutics: Outperforming with Strong Q2 Financials and Clinical Advancements

Biora Therapeutics granted extension to regain compliance with Nasdaq

Biora Therapeutics stock falls as it looks to raise $3M via direct offering

Biora Therapeutics Q3 Earnings Preview

Here are the major earnings after the close today

Biora Therapeutics GAAP EPS of -$5.04 misses by $1.19, revenue of $0.03M

Biora Therapeutics ( ($BIOR) ) has issued an announcement. Biora Therapeutics faced potential delisting from Nasdaq due to failing to meet the mark...

Biora Therapeutics Faces Nasdaq Delisting Challenges

AMAT

AQMS

AREC

ASND

ASTS

BIOR

BKKT

CNVS

CWCO

DARE

DESP

DNMR

GLOB

HYLN

IZEA

LCTX

LNVGY

OKLO

ORGN

POST

PPSI

PSTV

REKR

RSLS

SPRO

TTOO

VUZI

News

Press Releases

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Markets

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Biora Therapeutics Achieves ISO 13485 Certification

Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium

Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

Health Care

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Financing

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Earnings

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

ABVC BioPharma

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Bionomics Limited - American Depository Shares

Bionomics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Galecto

GRI Bio

GT Biopharma

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Moleculin Biotech

Onconetix

BiomX

Plus Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

T2 Biosystems

Vincerx Pharma

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics

Xenetic Biosciences

HC Wainwright & Co.

Comments

Biora Therapeutics

Biora Therapeutics (BIOR) Opzioni

Biora Therapeutics (NASDAQ:BIOR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO